- Home
- SAVA vs SANG Comparison
SAVA vs SANG Comparison
Compare SAVA & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- SANG
- Stock Information
- Founded
- SAVA 1998
- SANG 1984
- Country
- SAVA United States
- SANG Canada
- Employees
- SAVA N/A
- SANG N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- SANG Computer Software: Programming Data Processing
- Sector
- SAVA Health Care
- SANG Technology
- Exchange
- SAVA Nasdaq
- SANG Nasdaq
- Market Cap
- SAVA 137.2M
- SANG 158.2M
- IPO Year
- SAVA N/A
- SANG 2021
- Fundamental
- Price
- SAVA $1.38
- SANG $4.41
- Analyst Decision
- SAVA Buy
- SANG
- Analyst Count
- SAVA 3
- SANG 0
- Target Price
- SAVA $54.50
- SANG N/A
- AVG Volume (30 Days)
- SAVA 2.2M
- SANG 9.4K
- Earning Date
- SAVA 05-09-2025
- SANG 05-07-2025
- Dividend Yield
- SAVA N/A
- SANG N/A
- EPS Growth
- SAVA N/A
- SANG N/A
- EPS
- SAVA N/A
- SANG N/A
- Revenue
- SAVA N/A
- SANG $241,243,000.00
- Revenue This Year
- SAVA N/A
- SANG N/A
- Revenue Next Year
- SAVA N/A
- SANG $3.21
- P/E Ratio
- SAVA N/A
- SANG N/A
- Revenue Growth
- SAVA N/A
- SANG N/A
- 52 Week Low
- SAVA $1.35
- SANG $4.04
- 52 Week High
- SAVA $42.20
- SANG $7.99
- Technical
- Relative Strength Index (RSI)
- SAVA 23.37
- SANG 32.12
- Support Level
- SAVA $1.63
- SANG $4.22
- Resistance Level
- SAVA $1.79
- SANG $4.85
- Average True Range (ATR)
- SAVA 0.19
- SANG 0.18
- MACD
- SAVA -0.14
- SANG 0.04
- Stochastic Oscillator
- SAVA 1.76
- SANG 30.54
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.